PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12864879-1	2003	An interim analysis of the AASK trial at three years demonstrates a renoprotective effect [slower decline in glomerular filtration rate (GFR), delayed onset of significant decrease in GFR, end-stage renal disease (ESRD) or death, and a decrease in urinary protein excretion] of the angiotensin converting enzyme (ACE) inhibitor, ramipril, as compared to the dihydropyridine calcium channel blocker (DHP-CCB), amlodipine, in patients with mild-to-moderate renal insufficiency.	aask	27-31	dihydropyrimidinase	Homo sapiens	399-402	
11498655-4	2001	The AASK trial data suggest that DHP-CCBs should be used cautiously in the presence of mild to moderate renal insufficiency.	aask	4-8	dihydropyrimidinase	Homo sapiens	33-36